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Abstract 
Background: Regional citrate anticoagulation (RCA) is the recommended standard for 
continuous renal replacement therapy (CRRT). This study assesses its efficacy in patients 
admitted to critical care following cardiovascular surgery and the influence of standard 
antithrombotic agents routinely used in this specific group. 
Methods: Consecutive cardiovascular surgery patients treated with post-dilution 
hemofiltration with RCA were included in this prospective observational study. The primary 
outcome of the study was CRRT circuit life-span adjusted for reasons other than clotting. The 
secondary outcome evaluated the influence of standard antithrombotic agents (acetylsalicylic 
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acid [ASA], low molecular weight heparin [LMWH] or fondaparinux as thromboprophylaxis 
or treatment dose with or without ASA) on filter life.  
Results: Fifty-two patients underwent 193 sessions of CVVH, after exclusion of 15 sessions 
where unfractionated heparin was administered. The median filter life span was 58 hours. 
Filter life span was significantly longer in patients receiving therapeutic dose of LMWH or 
fondaparinux (79 h [2–110]), in comparison to patients treated with prophylactic dose of 
LMWH or fondaparinux (51 h [7–117], p < 0.001), and patients without antithrombotic 
prophylaxis (42 h [2–91], p < 0.0001). 12 bleeding episodes were observed; 8 occurred in 
patients receiving treatment dose anticoagulation, 3 in patients receiving prophylactic dose 
anticoagulation and 1 in a patient with no antithrombotic prophylaxis.  
Conclusions: A post dilution hemofiltration with RCA provides prolonged filter life span 
when adjusted for reasons other than clotting. Patients receiving treatment dose 
anticoagulation had a significantly longer filter life span than those who were on prophylactic 
doses or ASA alone. 
Key words: cardiovascular surgical procedures, continuous renal replacement therapy, 
hemofiltration, anticoagulants, citric acid 
 
 
Introduction 
Acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) 
after cardiac surgery affects between 2-5% of patients and carries a mortality rate between 36 
and 78% [1, 2]. Regional Citrate Anticoagulation (RCA) is the Kidney Disease-Improving 
Global Outcome (KDIGO) recommended anticoagulation of choice for continuous renal 
replacement therapy and is of particular value to patients with contraindications to heparin 
and high risk of bleeding such as those who have undergone cardiac surgery [3, 4]. RCA is 
also associated with a prolonged filter life-span due to a decreased incidence of clotting and 
preservation of the filter sieving coefficient for larger molecules including inflammatory 
mediators [5,6].  This anticoagulation modality was reported to be safe and preferred after 
cardiac surgery [7].  
Therefore, although RCA is commonly used in continuous veno-venous hemodialysis 
(CVVHD) and hemodiafiltration (CVVHDF) modes as these potentially offer reduced risk of 
clotting over purely convective modes, continuous veno-venous hemofiltration (CVVH) with 
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RCA on a high cut-off membrane may be of specific benefit to this group of patients 
providing filter life span remains long [8,9]. The Nikkiso Aquarius CRRT platform has been 
proven to be simple, effective and safe in delivering RCA through a post dilution CVVH 
method with a calcium containing replacement fluid in a general critical care population [10].   
Cardiac surgery patients often need postoperative antithrombotic prophylaxis but the 
type and dose varies. Most coronary surgery patients require antiplatelet therapy, while 
patients after valve surgery can be treated with bridge antithrombotic prophylaxis with 
unfractionated heparin (UFH) or low molecular weight heparin (LMWH), until they can reach 
therapeutic international normalized ratio (INR) values resulting from oral anticoagulants 
(OAC) administration though routine use remains open for debate [11].  
As RCA has been reported to improve filter survival in patients receiving systemic 
anticoagulation with UFH for indications other than CRRT, e.g. patients on veno-arterial 
extracorporeal membrane oxygenation (ECMO), it is the default anticoagulation method for 
CRRT in post cardiac surgery patients, in the absence of contraindications to citrate [12].  
This study aims to evaluate the effect of post dilution CVVH with RCA 
anticoagulation on filter life span in general in this specific group of patients, and whether 
routine thromboprophylaxis adds additional benefit.  
 
Methods 
The study protocol conformed to the Ethical Principles for Medical Research 
Involving Human Subjects outlined in the Declaration of Helsinki, was approved by the local 
institutional review board for scientific studies (NKBBN/539/2016-17) and is registered in the 
Clinical Trials database (NCT03836742). Consecutive cardiovascular surgery patients treated 
with CVVH RCA between September 2015 and November 2017 were included (Fig. 1).  
The decision to initiate renal replacement therapy was made by the treating clinician 
based on clinical features of volume overload and biochemical features of azotemia [3]. 
Contraindications to RCA were severe chronic liver disease, acute liver injury with INR > 2 
and refractory shock with lactate increasing above 8 mmol/L.  
 
Hemofiltration and RCA protocol 
Continuous veno-venous hemofiltration was performed with the Aquarius+ CRRT machine 
with version 6.02.14/15 software (Aquarius system, NIKKISO Europe GmbH, 
Desbrocksriede 1, 30855 Langenhagen, Germany) and CITRASET RCA for therapies with 
regional citrate anticoagulation comprising Aqualine RCA (Haemotronic S.p.A, Via Carreri 
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16, 41037 Mirandola, Italy) and AQUAMAX hemofilter (Nikkiso Belgium bvba, 
Industriepark 6, 3300 Tienen, Belgium). Filter size (either Aquamax 1.2 m2 or Aquamax 1.9 
m2) was determined by the treating clinician and depended on the patient’s actual body weight 
(> 90 kg) and or the presence of distributive shock requiring noradrenalin infusion over 0.1 
µg/kg/h, where an Aquamax 19 was used. In all patients Accusol 35 K0 (Nikkiso, Belgium 
Industriepark 6 B-3300 Tienen; Belgium), which contains 1.75mmol/L of Calcium, was used 
as the post dilution replacement fluid. Anticoagulant Citrate Dextrose Solution A, U.S.P. 
(ACD-A) (ACD-A, Macopharma, 5003F Rue Lorthiois, 59420 Mouvaux, France) was used as 
the source of citrate. 
Three thousand units of UFH were added to 1 liter 0.9% NaCl solution for CRRT 
circuit priming in all but 7 patients who had a suspicion of heparin induced thrombocytopenia.  
Initial settings of hemofiltration parameters and its modifications when metabolic 
alkalosis was observed, were adopted from the CVVH RCA protocol published by Kirwan et 
al. [10], however the renal dose was calculated for the actual body weight. 
The plasma concentration of ionized calcium (iCa) was augmented with additional 
calcium supplementation initially using a dose of 10 mL of 10% Calcium Chloride (WZF 
Polfa, Karolkowa Str. 22/24, Warsaw, Poland) added to 1 L of normal saline which resulted in 
Ca++ concentration of 4.6 mmol/L. Due to low ionized calcium plasma concentration, after the 
first 10 patients its dose was increased to 20 mL 10% calcium chloride, and after the 
following 10 patients to 40 mL 10% calcium chloride, equivalent to Ca++ concentration of 
18.4 mmol/L. The target calcium concentration in plasma was increased from the original 
0.9–1.2 range to a 1.0–1.2 range. Similarly, the original protocol was modified by an 
additional routine infusion of 0.2 g/h magnesium sulfate. 
Blood flow was set to achieve a filtration ratio of ~20%. If the plasma pH increased 
above 7.5 or bicarbonate concentration above 40 mmol/L the hemofiltration dose was 
decreased from the initial 35 mL/kg/h to 25 mL/kg/h. If metabolic alkalosis persisted, the 
citrate dose was reduced and if this did not resolve the issue within 3 h RCA was stopped 
[10].  
Either 13.5 Fr Mahurkar catheters (Covidien, 15 Hampshire Str., Mansfield, MA 
02048USA) or 12 Fr Hemo-Access (Biometrix Ltd., 4 Kiryat Mada, Jerusalem, Israel) with 
length depending on cannulation site were used, however the type of the catheter was not 
reported in patients’ files.  
Primary endpoint of this study was to assess filter lifespan in post dilution CVVH with 
RCA in cardiovascular surgery patients. Secondary endpoint evaluated the difference in filter 
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life span depending on standard antithrombotic agents by separating hemofiltration sessions 
into three groups; Group A: no antithrombotic medication or acetylsalicylic acid (ASA) alone; 
Group B: prophylactic dose LMWH or fondaparinux, with or without ASA; Group C: 
treatment dose LMWH or fondaparinux with or without ASA. Fondaparinux was used instead 
of LMWH whenever HIT was suspected and HIT ELISA test was positive [13]. 
Treatment sessions where continuous unfractionated heparin (UFH) added for 
therapeutic reasons were excluded from filter survival analysis.  
 
Statistical analysis 
Data are presented as median, quartiles and ranges. CRRT circuit lifespan is presented 
as Kaplan-Meier curves. Categorical variables were compared between groups with the chi-
square test. Inter-group differences in filter lifespan were assessed with the Cox-Mantel test. 
 
Results  
Two hundred and eight CVVH sessions were performed in 52 patients (including 4 
chronic dialysis patients). Fifteen sessions were excluded as the patients received an 
additional UFH infusion. Patients characteristics and cardio-vascular surgical procedures are 
presented in Table 1.  
 
Primary endpoint 
Filter life span of 193 sessions was adjusted for reasons to stop the filter other than 
clotting (96) and these included patient death (3), clinical decision (14), transport to computed 
tomography scan (2), change of therapy (2), technical (3: 1 alkalosis, 1 machine failure, 1 
access concern) and end of filter life span (73).  
Median time CRRT circuit lifespan was 58 h (2–117). CRRT circuit lifespan reached 
the 72-h manufacturer cut off in 75 (38.9%) sessions (Fig. 2).  
 
Secondary endpoint  
A significantly longer filter life span was observed in RCA CVVH sessions when 
patients received a treatment dose LMWH or fondaparinux (Table 2, Fig. 3).   
Bleeding complications were observed in 12 patients (23%) (6 major) during or after 
CRRT and are presented in Table 3. Nine patients with bleeding complications were treated 
with treatment dose LMWH or fondaparinux, one with UFH, one with prophylactic dose 
LMWH and one with ASA alone (NS).  
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Discussion 
According to available research, this is the first study of post dilution CVVH with 
RCA anticoagulation in postoperative cardiovascular surgery patients. It is safe and effective 
treatment leading to a median filter life of 58 h when adjusted for reasons other than clotting. 
The present results compare well with similar studies, using this protocol in a general 
intensive care unit (ICU) population (27 h) and postoperative cardiac surgical patients who 
received RCA predilution continuous hemofiltration (48 h), continuous hemodiafiltration with 
RCA or heparin (50–58 h) and continuous hemodialysis with RCA (39–61 h) [10, 14–20]. 
Most of these studies, however, did not specifically address the question of whether the 
patients received any systemic antithrombotic prophylaxis. 
Although this is only a pilot study it is the first to demonstrate significant differences 
in RCA CVVH filter lifespan between patients receiving additional systemic anticoagulation 
medications that are often required following cardiovascular surgery. This data is in line with 
a similar study of general ICU patients by Wu et al. [21] where the addition of low dose 
dalteparin to high volume predilution CVVH with RCA improved filter life span from 25 to 
40 h, without increasing the risk of bleeding, and thus plays an important role when 
evaluating the success of filter specific anticoagulation or when comparing filter life span in 
cardiac patients and general ICU populations [21]. 
The incidence of bleeding is an important marker of treatment safety during CRRT. 
RCA reduces bleeding complications but many postoperative cardiac patients receive 
additional anticoagulants [11]. In the current study, major and minor bleeding complications 
observed in 8 patients were related to treatment dose anticoagulation. High incidence of 
bleeding complications observed in the present group of patients treated with CRRT was 
unlikely to be related to CRRT circuit anticoagulation but to post cardiovascular surgery 
antithrombotic prophylaxis. It is a matter of ongoing discussion if LMWH or UFH bridging is 
indispensable after valve surgery [11].  
An appropriately powered study to assess bleeding complications when prophylactic 
LMWH or fondaparinux is added, is needed before this can be recommended as a routine 
addition to RCA CRRT therapy to increase filter survival alone and this will be difficult to do. 
A limitation of the current study is that we assessed hemofiltration sessions during which 
different antithrombotic prophylaxis were compared. In some patients different 
antithrombotic regimens were used depending on their clinical status. For example, if the 
mechanical mitral valve replacement patient was treated with CRRT in the early postoperative 
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hours due to anuria, no antithrombotic prophylaxis was used due to the risk of bleeding. The 
same patient would however receive treatment dose of LMWH a few days later, often after 
the chest drains were removed. A more complex statistical comparison of bleeding episodes 
between the groups would be needed to evaluate the risk of bleeding post operatively, as well 
as a more formalized assessment of bleeding risk depending on time after surgery.  
There are some clear limitations to this pilot study. It was not possible to capture data 
on catheter type and tip position, something which has been shown to play an important role 
in filter survival regardless of anticoagulation method [22].  
Similarly, other factors potentially affecting circuit life span including platelet count 
and other measures of clotting function (e.g. analysis of thromboelastography) were not 
collected. Future studies of filter life span would benefit from including these laboratory data 
to determine if they are relevant in the clinical setting.  
The life span of hemofiltration circuit can also be affected by multiple clinical factors 
including type of surgery, duration of surgery and cardiopulmonary bypass, aortic cross-
clamp time, use of vasopressors, etc. A much larger study would be needed to individually 
evaluate these and it may not be of overall benefit.  
There is however an additional potential benefit of demonstrating a good filter life 
span outcome with CVVH. A recent study revealed that after cardiac surgery postoperative 
inflammatory response is severe enough to fulfill SIRS criteria in as many as 28% of patients 
[23]. Data from experimental and clinical studies, suggest that convection might be more 
effective than diffusion in the clearance of middle- and high-molecular weight particles at the 
equivalent dose, but the clinical benefit of convection above dialysis has not been shown [24].  
In the original Royal London Hospital RCA protocol, a lower target citrate 
concentration (2.8 mmol/L) in the filter was accepted, in comparison to most RCA protocols 
for hemodialysis. ACD-A citrate solution was used instead of trisodium citrate solution, most 
commonly used throughout Europe, in order to reduce the risk of metabolic alkalosis resulting 
from citrate metabolism, and to decrease sodium load. It was presumed that target citrate 
concentration in the filter equal to 2.8 mmol/L should decrease ionized calcium concentration 
in the filter to 0.35 mmol/L on the average.  
Some modifications were made to the original Royal London CVVH with RCA 
treatment formula. Firstly, actual body weight instead of ideal body weight was used for renal 
dose calculation. The rationale for it was that patients after recent cardiovascular surgery have 
significant catabolism, and the authors intended to use a higher clearance, rather than too low 
of a clearance of solutes. 
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Secondly, the target plasma calcium concentration was higher in comparison to the 
original protocol. In order to achieve this goal, calcium concentration in calcium replacement 
solution was stepwise increased after initial experience, from 4.6 mmol/L to a final 18.4 
mmol/L. Higher range of target calcium concentration could potentially slightly increase the 
risk of filter clotting, because with a higher plasma ionized calcium concentration and equal 
dose of citrate, ionized calcium concentration in the filter could also be slightly increased in 
comparison to the observations of the authors of the original protocol. A target plasma ionized 
calcium concentration was increased in order to minimize the risk of hypocalcemia, which 
could contribute to exacerbating post cardiotomy heart failure and cause calcium resorption 
from bones during prolonged treatment of patients immobilized by their critical condition. 
Hight cut-off (55 kDa) filters used in the study patients might theoretically promote 
convective cytokine removal, but its efficacy was not specifically studied in post cardiac 
surgery patients with AKI. This effect may be beneficial in the early postoperative hours after 
cardiopulmonary bypass (CPB) cardiac surgery where high concentrations of cytokines and 
chemokines can play a significant role in contributing to increased postoperative morbidity 
and mortality and using the present protocol may be a way, in future, of evaluating its 
potential benefit [25, 26]. To add further impetus in performing this type of   study, there is 
some experimental rationale to preference RCA when initiating CRRT for postoperative 
cardiac patients. RCA is related to less complement and neutrophil activation in comparison 
to heparin, which may be an important factor in cardiac surgery patients, in whom 
complement and neutrophil activation by cardiopulmonary bypass, contributes to 
postoperative complications [27]. Citrate has been shown to exert cardio- and reno-protective 
effects in acute kidney injury triggered by ischemia-reperfusion in rats but this is yet to be 
shown in the clinical setting [28]. An improvement of survival in critically ill surgical patients 
treated with RCA in comparison to LMWH was observed by Oudemans-Van Straaten but it 
was not confirmed by subsequent studies [4, 29].  
 
Conclusions 
In summary, post dilution CVVH RCA for postoperative cardiovascular surgery 
patients results in excellent filter life span when compared to data from other groups of 
similar patients. The addition of treatment dose LMWH/fondaparinux required for post 
cardiac surgery antithrombotic prophylaxis significantly increases filter life span, but may 
carry a risk of increased incidence of bleeding episodes. Further studies are needed to 
determine whether routine additional anticoagulation is beneficial and whether a CVVHF post 
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dilution RCA protocol, that affords long filter life spans, can add additional mortality and 
morbidity benefit to postoperative cardiac surgical patients with renal failure over other 
modes of CRRT. 
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Figure 1. The flow-chart of hemofiltration sessions included into continuous renal 
replacement therapy (CRRT) circuit lifespan analysis; HF — heart failure; UFH — 
unfractionated heparin.  
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Figure 2. Kaplan-Meier curve of filter survival censored for discontinuation due to reasons 
other than circuit clotting. 
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Figure 3. Influence of systemic antithrombotic prophylaxis on continuous renal replacement 
therapy (CRRT) circuit lifespan. (Group A: No antithrombotic prophylaxis or acetylsalicylic 
acid [ASA] only, Group B: prophylactic dose low molecular weight heparin [LMWH] or 
fondaparinux with or without ASA, Group C: more than prophylactic dose LMWH or 
fondaparinux with or without ASA). 
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Table 1. Patient characteristics and type of surgical procedures in the study group. 
Patient characteristics/type of surgery Data/Number of patients 
Patients age 70 (Q1 = 62, Q3 =74; range: 37–84) 
Sex (male) 28 
Preexisting renal disease 24 
ESRF/Chronic dialysis treatment 4 
Diabetes mellitus 12 
Arterial hypertension 34 
COPD 4 
Hyperthyroidism 3 
Hypothyroidism 3 
Chronic atrial fibrillation 11 
Preoperative hemoglobin <10 [g/dL] 16 
Preoperative creatinine concentration [mg/dL] 1.49 (Q1 = 1.05, Q3 =2.11; range: 0.62–6.18) 
Type of surgery:  
Valvular surgery 23 
Revascularization surgery (CABG and OPCABG) 7 
Valvular + revascularization 6 
Cardiac other 2 
Vascular surgery including thoracic aorta surgery 10 
Extracorporeal support (ECMO/VAD) 1 
Heart transplant 1 
Pericardial drainage  1 
PM electrodes removal 1 
Hospital mortality 29 (57%) 
CABG — coronary artery bypass graft; COPD — chronic obstructive pulmonary disease; 
ECMO — extracorporeal membrane oxygenation; ESRF — end-stage renal failure; PM — 
pacemaker; OPCABG — off-pump coronary artery bypass graft; VAD — ventricular assist 
device 
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Table 2. Systemic antithrombotic prophylaxis used during regional citrate anticoagulation 
continuous veno-venous hemofiltration sessions. 
Antithrombotic agents Number of 
hemofiltration 
sessions 
Median circuit 
lifespan hours 
(range) 
G
ro
u
p
 A
 
(N
 =
 5
6
) 
No antithrombotic medication 51  
42 (2–91) 
ASA alone 5 
G
ro
u
p
 B
 (
N
 =
 6
2
) Prophylactic dose low molecular weight 
heparin (LMWH) without ASA 
29  
 
51 (7–117) Prophylactic dose LMWH with ASA 16 
Prophylactic dose fondaparinux without ASA  17 
Prophylactic dose fondaparinux with ASA 0 
G
ro
u
p
 C
 (
N
 =
 
7
5
) 
Treatment dose LMWH without ASA 44  
 
79 (2–110) 
Treatment dose LMWH with ASA  26 
Treatment dose fondaparinux without ASA 5 
Treatment dose fondaparinux with ASA 0 
ASA — acetylsalicylic acid; LMWH — low molecular weight heparin 
 
 
Table 3. Bleeding complications in the study group. Information on systemic antithrombotic 
prophylaxis refers to the highest dose during the whole hemofiltration treatment. 
Type of bleeding Surgical 
procedure 
Systemic antithrombotic 
prophylaxis 
Remarks Survival 
Hematoma of ascending 
colon mesentery 
AVR, MVR LMWH therapeutic dose  No 
Airway bleeding (Minor) Cardiac 
sarcoma 
resection  
LMWH therapeutic dose Idiopathic 
thrombocytopenia 
before surgery  
No 
Airway bleeding (Minor) CABG Fondaparinux prophylactic 
dose 
HIT suspected No 
Retroperitoneal 
hematoma 
MVR, TVP, 
ASD-closure, 
CABG 
Fondaparinux therapeutic 
dose 
Suspected relation to 
dialysis catheter 
inserted through 
femoral vein 
No 
Mediastina hematoma, 
gastro-duodenal bleeding  
AVR No prophylaxis or ASA 
only 
 No 
Airway bleeding (Minor) TVP LMWH therapeutic dose  No 
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Airway bleeding and oral 
cavity mucosal bleeding 
(Minor) 
OPCABG LMWH therapeutic dose, 
at 3rd session replaced with 
fondaparinux prophylactic 
dose 
HIT suspected No 
Airway bleeding (Minor) MVR LMWH therapeutic dose Thrombocytopenia No 
Retroperitoneal bleeding 
in the iliopsoas muscle 
area  
AVR LMWH therapeutic dose Suspected relation to 
dialysis catheter 
inserted through 
femoral vein 
Yes 
Oral cavity mucosal 
bleeding (Minor) 
AVR, CABG LMWH therapeutic dose  No 
Femoral hematoma after 
IABP removal 
VA ECMO, 
IABP 
UFH infusion Myocarditis was an 
indication to VA 
ECMO 
Yes 
Retroperitoneal bleeding 
in the iliac muscle area 6 
days after the end of 
hemofiltration treatment 
MVR LMWH therapeutic dose HIT, endocarditis 
was an indication to 
MVR, bleeding 6 
days after the end of 
hemofiltration, 
Suspected relation to 
dialysis catheter 
inserted through 
femoral vein 
Yes 
ASD — atrial septal defect; AVR — aortic valve replacement; CABG — coronary artery bypass graft; HIT — 
heparin induced thrombocytopenia; IABP — intra aortic balloon pump; LMWH — low molecular weight 
heparin; MVR — mitral valve replacement; OPCABG — off-pump coronary artery bypass graft; TVP — 
tricuspid valve plastic; UFH — unfractionated heparin; VAD — ventricular assist device; VA ECMO — veno-
arterial extracorporeal membrane oxygenation 
 
 
